Efectividad del sistema MiniMed 640G con SmartGuard® para la prevención de hipoglucemia en pacientes pediátricos con diabetes mellitus tipo 1

GROUPA, Complications Trial Research, et al. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J. Pediatr. 1994;125(2):177-188. 1998, Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial, Ann Intern Med., 128, 517, 10.7326/0003-4819-128-7-199804010-00001 Weiss, 2015, Predictors of hypoglycemia in the ASPIRE In-Home Study and effects of automatic suspension of insulin delivery, J Diabetes Sci Technol., 9, 1016, 10.1177/1932296815586014 1991, Epidemiology of severe hypoglycemia in the diabetes control and complications trial, Am J Med, 90, 450, 10.1016/0002-9343(91)80085-Z Buckingham, 2008, Duration of nocturnal hypoglycemia before seizures, Diabetes Care., 31, 2110, 10.2337/dc08-0863 Tanenberg, 2010, Confirmation of hypoglycemia in the dead-in-bed syndrome, as captured by a retrospective continuous glucose monitoring system, Endocr Pract., 16, 244, 10.4158/EP09260.CR Driscoll, 2016, Fear of hypoglycemia in children and adolescents and their parents with type 1 diabetes, Current Diabetes Reports., 16, 1, 10.1007/s11892-016-0762-2 Ho, 2008, Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus, J Pediatr., 153, 385, 10.1016/j.jpeds.2008.03.005 Snell-Bergeon, 2012, Cardiovascular disease risk in young people with type 1 diabetes, J of Cardiovasc Trans Res., 5, 446, 10.1007/s12265-012-9363-x Bergenstal, 2013, Threshold-based insulin-pump interruption for reduction of hypoglycemia, N Engl J Med., 369, 224, 10.1056/NEJMoa1303576 Garg, 2012, Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study, Diabetes Technol Ther., 14, 205, 10.1089/dia.2011.0292 Buckingham, 2013, Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia, Diabetes Technol Ther., 15, 622, 10.1089/dia.2013.0040 Choudhary, 2016, Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management, Diabetes Technol Ther., 18, 288, 10.1089/dia.2015.0324 Danne, 2014, The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise, Diabetes Technol Ther., 16, 338, 10.1089/dia.2013.0327 Biester, 2017, Let the algorithm do the work: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients, Diabetes Technol Ther., 10.1089/dia.2016.0349 Abraham, 2016, Prevention of insulin-induced hypoglycemia in type 1 diabetes with predictive low glucose management system, Diabetes Technol Ther., 18, 436, 10.1089/dia.2015.0364 Buckingham, 2015, Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis, Diabetes Care., 38, 1197, 10.2337/dc14-3053 Beck, 2014, Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system, Diabetes Care., 37, 1224, 10.2337/dc13-2775 Abraham, 2016, Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomized controlled home trial to evaluate the Suspend Before Low function, BMJ open., 6, e011589, 10.1136/bmjopen-2016-011589 Lou, 2016, Our experience with sensor-augmented-pump therapy for children, Pediatr Diabetes, 17 Gawel, 2016, Introduction of personal insulin pump 640G therapy with SmartGuard technology reduces the negative impact of diabetes on life comfort of patients with type 1 diabetes, Pediatr Diabetes, 17 Rubin, 2009, Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump, J Diabetes Sci Technol., 3, 1402, 10.1177/193229680900300621 Sherr, 2014, Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose, Diabetes Care., 37, 773, 10.2337/dc13-1608